Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EX108
- Development stage
- Preclinical
- Lead developer
- Excelmab
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
EX108 is a preclinical-stage bispecific T-cell engager (BiTE) developed by Guangzhou Excelmab for the treatment of mesothelin-expressing solid tumors, such as ovarian cancer, mesothelioma, and pancreatic cancer. The therapeutic utilizes a 2:1 nanobody-based molecular architecture, incorporating two nanobody domains specific for mesothelin (MSLN) and one domain targeting the CD3 epsilon chain on T cells. This design aims to optimize tumor-selective binding and potent T-cell activation within the tumor microenvironment to drive anti-tumor efficacy. As of 2024, the program is in the preclinical candidate (PCC) stage of development.
02
Targets
CD3 (T-cell surface glycoprotein CD3)TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on EX108.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EX108.